AXL Inhibitor

SLC-391 is a novel, highly selective small-molecule compound that inhibits the activity of AXL, a receptor tyrosine kinase of the TAM family, which is over-expressed or over-activated in almost all cancer types and directly correlates with tumor stage and prognosis. AXL appears to play a dual regulatory role, controlling the initiation and progression of tumor development and the associated antitumor responses of diverse immune cells. As such, AXL represents an intriguing protein to simultaneously target the tumor cells and the immune cells in the TME.

Carbonic Anhydrase IX (CAIX) Inhibitor

SLC-0111 is a first-in-class small molecule inhibitor of Carbonic Anhydrase IX (CAIX), which is only expressed on the surface of human tumor cells. The drug aims to regulate the tumor microenvironment, suppress the survival of tumor cells, especially tumor stem cells, and prevent the metastasis and recurrence of cancer.

RON (Recepteur d'Origine Nantais) Inhibitor

SLC-500 is a small-molecule inhibitor of receptor tyrosine kinase RON (Recepteur d'Origine Nantais) that belongs to the mesenchymal-to-epithelial transition (MET) family. Further optimization is currently underway to improve its potency and selectivity.

Colony-stimulating factor 1 Receptor (CSF1R) Inhibitor

Our CSF1R program aims to develop a first-in-class CSF1R and ICI combination therapy to improve the ICI responsiveness and to overcome ICI resistance through the multifactorial modulation of immune responses.

Next-Gen Ferroptosis-Inducer

SLC-700 aims to develop a small-molecule inhibitor that possesses enhanced ferroptosis-inducing activity, with the goal of promoting ferroptosis of hypoxic cancer cells.

On-going clinical studies: indications, patients, links to clinicaltrials.gov.